{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:04:01Z","timestamp":1766023441588,"version":"3.48.0"},"reference-count":26,"publisher":"e-Century Publishing Corporation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/gsyn6858","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T08:15:09Z","timestamp":1757060109000},"page":"6619-6629","source":"Crossref","is-referenced-by-count":0,"title":["Alternating intravesical instillation of Bacillus Calmette-Guérin and Pseudomonas aeruginosa effectively prevents postoperative recurrence in high-risk non-muscle-invasive bladder cancer"],"prefix":"10.62347","volume":"17","author":[{"given":"Yiqun","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","unstructured":"Al Hussein Al Awamlh B and Chang SS. Novel therapies for high-risk non-muscle invasive bladder cancer. Curr Oncol Rep 2023; 25: 83-91.","journal-title":"Curr Oncol Rep"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE and Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33.","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","unstructured":"Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM Jr and Lerner SP. Phase 2 trial of atezolizumab in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605. Eur Urol 2023; 84: 536-544.","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) studies: Systematic Literature Review (SLR)","volume":"14","author":"Musat","year":"2022","unstructured":"Musat MG, Kwon CS, Masters E, Sikirica S, Pijush DB and Forsythe A. Treatment outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) studies: Systematic Literature Review (SLR). Clinicoecon Outcomes Res 2022; 14: 35-48.","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P, Geiges G, Pohlmann J and Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol 2023; 13: 1170124.","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1143219","DOI":"10.3389\/fsurg.2023.1143219","article-title":"Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: current landscape and future directions","volume":"10","author":"Sun","year":"2023","unstructured":"Sun X, Dai T and Xu L. Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: current landscape and future directions. Front Surg 2023; 10: 1143219.","journal-title":"Front Surg"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Li A, Fang W, Zhang F, Li W, Lu H, Liu S, Wang H and Zhang B. Transurethral resection and degeneration of bladder tumour. Can Urol Assoc J 2013; 7: E812-816.","DOI":"10.5489\/cuaj.363"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/fon-2023-0271","article-title":"CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer","volume":"20","author":"Steinberg","year":"2024","unstructured":"Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D and Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer. Future Oncol 2024; 20: 891-901.","journal-title":"Future Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Guerin (BCG) therapy for bladder cancer: an update","volume":"9","author":"Guallar-Garrido","year":"2020","unstructured":"Guallar-Garrido S and Julian E. Bacillus Calmette-Guerin (BCG) therapy for bladder cancer: an update. Immunotargets Ther 2020; 9: 1-11.","journal-title":"Immunotargets Ther"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Longoni M, Scilipoti P, Soria F, Pradere B, Krajewski W, D’Andrea D, Mari A, Del Giudice F, Pichler R, Subiela JD, Afferi L, Albisinni S, Gallioli A, Mertens LS, Laukhtina E, Mori K, Radziszewski P, Slusarczyk A, Shariat SF, Necchi A, Xylinas E, Gontero P, Roupret M, Montorsi F, Briganti A and Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. Oncological Outcomes in Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives. Eur Urol Oncol 2025; S2588-9311(25)00081-1.","DOI":"10.1016\/j.euo.2025.03.007"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/onc.2010.70","article-title":"Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner","volume":"29","author":"Liu","year":"2010","unstructured":"Liu ZB, Hou YF, Zhu J, Hu DL, Jin W, Ou ZL, Di GH, Wu J, Shen ZZ and Shao ZM. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene 2010; 29: 2996-3009.","journal-title":"Oncogene"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/liv.12644","article-title":"Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR\/Akt\/IkappaBbeta\/NF-kappaB pathway","volume":"35","author":"Li","year":"2015","unstructured":"Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZQ and Hu SY. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR\/Akt\/IkappaBbeta\/NF-kappaB pathway. Liver Int 2015; 35: 1416-1429.","journal-title":"Liver Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00262-021-03063-7","article-title":"Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model","volume":"71","author":"Wang","year":"2022","unstructured":"Wang B, He Z, Yu H, Ou Z, Chen J, Yang M, Fan X, Lin T and Huang J. Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model. Cancer Immunol Immunother 2022; 71: 1507-1517.","journal-title":"Cancer Immunol Immunother"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS and Gillessen S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org . Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 244-258.","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/bco2.305","article-title":"Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines","volume":"5","author":"Miyake","year":"2023","unstructured":"Miyake M, Kitamura H, Nishimura N, Miyamoto T, Nakahama T, Fujii T, Matsumoto H, Matsuyama H, Yonemori M, Enokida H, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Nishiyama H and Fujimoto K; Nishinihon Uro-oncology Extensive Collaboration group and the Japanese Urological Oncology Group. Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines. BJUI Compass 2023; 5: 269-280.","journal-title":"BJUI Compass"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/diagnostics12051154","article-title":"The role of adjuvant single postoperative instillation of gemcitabine for non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"12","author":"Koimtzis","year":"2022","unstructured":"Koimtzis G, Alexandrou V, Chalklin CG, Carrington-Windo E, Ramsden M, Karakasis N, Lam KW and Tsakaldimis G. The role of adjuvant single postoperative instillation of gemcitabine for non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Diagnostics (Basel) 2022; 12: 1154.","journal-title":"Diagnostics (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1245\/s10434-023-14488-y","article-title":"Gemcitabine with cisplatin versus hepatic arterial infusion pump chemotherapy for liver-confined unresectable intrahepatic cholangiocarcinoma","volume":"31","author":"Franssen","year":"2024","unstructured":"Franssen S, Holster JJ, Jolissaint JS, Nooijen LE, Cercek A, D’Angelica MI, Homs MYV, Wei AC, Balachandran VP, Drebin JA, Harding JJ, Kemeny NE, Kingham TP, Klumpen HJ, Mostert B, Swijnenburg RJ, Soares KC, Jarnagin WR and Groot Koerkamp B. Gemcitabine with cisplatin versus hepatic arterial infusion pump chemotherapy for liver-confined unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol 2024; 31: 115-124.","journal-title":"Ann Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4103\/jcrt.jcrt_2271_22","article-title":"Concurrent chemoradiation with low-dose and long-duration weekly infusion of gemcitabine in unresectable squamous cell carcinoma of head and neck (SCCHN)","volume":"20","author":"Ahmad","year":"2024","unstructured":"Ahmad F, Akram M and Khan M. Concurrent chemoradiation with low-dose and long-duration weekly infusion of gemcitabine in unresectable squamous cell carcinoma of head and neck (SCCHN). J Cancer Res Ther 2024; 20: 827-831.","journal-title":"J Cancer Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3892\/ol.2024.14400","article-title":"Perfusion drugs for non-muscle invasive bladder cancer (Review)","volume":"27","author":"Qian","year":"2024","unstructured":"Qian J, Zhang Q, Cao Y, Chu X, Gao Y, Xu H, Cai H and Wu J. Perfusion drugs for non-muscle invasive bladder cancer (Review). Oncol Lett 2024; 27: 267.","journal-title":"Oncol Lett"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bju.16675","article-title":"Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer","volume":"136","author":"Scilipoti","year":"2025","unstructured":"Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, Pradere B, Krajewski W, D’Andrea D, Mari A, Del Giudice F, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Rodriguez Elena JL, Aranda J, Puentedura AL, Cano Velasco J, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Necchi A, Roupret M, Montorsi F, Salonia A, Briganti A and Moschini M; European Association of Urology - Young Academic Urologists (EAU - YAU), Urothelial Carcinoma Working Group. Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer. BJU Int 2025; 136: 47-54.","journal-title":"BJU Int"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T and de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021; 22: 919-930.","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1007\/s13277-013-1559-4","article-title":"The mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa shift peritoneal milky spot macrophages towards an M1 phenotype to dampen peritoneal dissemination","volume":"35","author":"Miao","year":"2014","unstructured":"Miao ZF, Zhao TT, Miao F, Wang ZN, Xu YY, Mao XY, Gao J, Wu JH, Liu XY, You Y, Xu H and Xu HM. The mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa shift peritoneal milky spot macrophages towards an M1 phenotype to dampen peritoneal dissemination. Tumour Biol 2014; 35: 4285-4293.","journal-title":"Tumour Biol"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Hu J, Ye F, Cui M, Lee P, Wei C, Hao Y, Wang X, Wang Y, Lu Z, Galsky M, McBride R, Wang L, Wang D, Cordon-Cardo C, Wang C and Zhang DY. Protein profiling of bladder urothelial cell carcinoma. PLoS One 2016; 11: e0161922.","DOI":"10.1371\/journal.pone.0161922"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Setianingsih YA, Djatisoesanto W, Laksita TB and Aryati A. Diagnostic accuracy of urinary cytokeratin fragment-19 (CYFRA21-1) for bladder cancer. Narra J 2024; 4: e1142.","DOI":"10.52225\/narra.v4i3.1142"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.31557\/APJCP.2023.24.6.2021","article-title":"Sequential application and post-test probability for screening of bladder cancer using urinary proteomic biomarkers: a review based probabilistic analysis","volume":"24","author":"Bhongir","year":"2023","unstructured":"Bhongir AV, Sampath S, Bonthapally RK, Gudivada KK and Ramaswamy G. Sequential application and post-test probability for screening of bladder cancer using urinary proteomic biomarkers: a review based probabilistic analysis. Asian Pac J Cancer Prev 2023; 24: 2021-2027.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective","volume":"19","author":"Teoh","year":"2022","unstructured":"Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF and Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol 2022; 19: 280-294.","journal-title":"Nat Rev Urol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/8\/ajtr0166128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:59:14Z","timestamp":1766023154000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/8\/ajtr0166128.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/gsyn6858","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2025]]}}}